yan lun jie - Search Results

Year	Number of Results
2019	2
2020	1
2021	5
2022	14
2023	21
2024	4

1

Diacylglycerol lipase alpha promotes hepatocellular carcinoma progression and induces lenvatinib resistance by enhancing YAP activity.

Yan YC, Meng GX, Yang CC, Yang YF, Tan SY, Yan LJ, Ding ZN, Ma YL, Dong ZR, Li T. Yan YC, et al. Among authors: yan lj. Cell Death Dis. 2023 Jul 6;14(7):404. doi: 10.1038/s41419-023-05919-5. Cell Death Dis. 2023. PMID: 37414748 Free PMC article.

2

MALAT1/ mir-1-3p mediated BRF2 expression promotes HCC progression via inhibiting the LKB1/AMPK signaling pathway.

Li GZ, Meng GX, Pan GQ, Zhang X, Yan LJ, Li RZ, Ding ZN, Tan SY, Wang DX, Tian BW, Yan YC, Dong ZR, Hong JG, Li T. Li GZ, et al. Among authors: yan lj. Cancer Cell Int. 2023 Aug 31;23(1):188. doi: 10.1186/s12935-023-03034-1. Cancer Cell Int. 2023. PMID: 37653482 Free PMC article.

3

Caffeine intake is associated with less severe depressive symptoms in noncancer populations: an analysis based on NHANES 2007-2016.

Yang LS, Zhang ZY, Yan LJ, Yan YC, Tan SY, Wang DX, Dong ZR, Li T. Yang LS, et al. Among authors: yan lj. Nutr Res. 2023 Oct;118:1-11. doi: 10.1016/j.nutres.2023.07.004. Epub 2023 Jul 18. Nutr Res. 2023. PMID: 37531810

4

Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose-response meta-analysis.

Yan LJ, Yang LS, Yan YC, Tan SY, Ding ZN, Liu H, Wang DX, Dong ZR, Li T. Yan LJ, et al. Eur J Cancer. 2023 May;185:150-163. doi: 10.1016/j.ejca.2023.03.005. Epub 2023 Mar 8. Eur J Cancer. 2023. PMID: 36996625

5

Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.

Tian BW, Han CL, Wang HC, Yan LJ, Ding ZN, Liu H, Mao XC, Tian JC, Xue JS, Yang LS, Tan SY, Dong ZR, Yan YC, Wang DX, Li T. Tian BW, et al. Among authors: yan lj. Clin Exp Metastasis. 2023 Aug;40(4):255-287. doi: 10.1007/s10585-023-10217-7. Epub 2023 Jun 13. Clin Exp Metastasis. 2023. PMID: 37308706

6

A model based on adipose and muscle-related indicators evaluated by CT images for predicting microvascular invasion in HCC patients.

Mao XC, Shi S, Yan LJ, Wang HC, Ding ZN, Liu H, Pan GQ, Zhang X, Han CL, Tian BW, Wang DX, Tan SY, Dong ZR, Yan YC, Li T. Mao XC, et al. Among authors: yan lj. Biomark Res. 2023 Oct 4;11(1):87. doi: 10.1186/s40364-023-00527-z. Biomark Res. 2023. PMID: 37794517 Free PMC article.

7

Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.

Li H, Liu H, Yan LJ, Ding ZN, Zhang X, Pan GQ, Han CL, Tian BW, Tan SY, Dong ZR, Wang DX, Yan YC, Li T. Li H, et al. Among authors: yan lj. Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(11):1159-1167. doi: 10.1080/17474124.2023.2279175. Epub 2023 Nov 23. Expert Rev Gastroenterol Hepatol. 2023. PMID: 37929312 Review.

8

Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis.

Liu H, Yang CC, Ma YL, Yang YF, Yan LJ, Ding ZN, Xue JS, Yang LS, Yan YC, Dong ZR, Wang DX, Chen ZQ, Hong JG, Li T. Liu H, et al. Among authors: yan lj. Immunotherapy. 2023 Jun;15(9):669-678. doi: 10.2217/imt-2022-0114. Epub 2023 May 4. Immunotherapy. 2023. PMID: 37140011 Review.

9

Regional and sex differences in the mortality risk associated with primary liver cancer in obesity: A systematic review and meta-analysis.

Yang LS, Yan LJ, Yan YC, Ding ZN, Liu H, Tan SY, Dong ZR, Wang DX, Li T. Yang LS, et al. Among authors: yan lj. Nutrition. 2023 Sep;113:112097. doi: 10.1016/j.nut.2023.112097. Epub 2023 May 25. Nutrition. 2023. PMID: 37406391 Review.

10

Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.

Han CL, Tian BW, Yan LJ, Ding ZN, Liu H, Mao XC, Tian JC, Xue JS, Tan SY, Dong ZR, Yan YC, Hong JG, Chen ZQ, Wang DX, Li T. Han CL, et al. Among authors: yan lj. Cancer Immunol Immunother. 2023 Jul;72(7):1957-1969. doi: 10.1007/s00262-023-03390-x. Epub 2023 Feb 22. Cancer Immunol Immunother. 2023. PMID: 36811662 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

39 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year